The short answer
Avoid adding kava to primidone without the prescriber’s review. Kava guidance advises against combining it with sedating substances, and primidone can impair alertness.
What this answer covers
Oral Piper methysticum products; exact extract, dose and co-ingredients matter.
- Supplement or preparation
- Piper methysticum
- Medication ingredient
- primidone
Why the combination needs review
NCCIH advises against combining kava with sedative substances. The concern here is additional impairment; a sleep or anxiety benefit in another setting would not establish safety of this combination.
What the clinical reports do not show
A controlled kava trial did not find benefit for its primary anxiety outcome. That trial was not a safety test with this medication. There is no basis to assume primidone and its metabolites respond identically to an untested kava product.
Do not use spacing as a workaround
No validated time gap makes this combination safe. Bring the full kava label and describe regular or heavy use so the clinician can plan any changes rather than relying on a few hours between doses.
Watch for impaired alertness
Primidone can cause drowsiness and impaired coordination. Avoid driving when affected, and seek urgent help for severe difficulty waking or breathing. Other sedating medicines and alcohol make a careful medication review especially important.
Evidence and practical considerations
Side effects & toxicity
Conditional avoidance/review is supported by botanical guidance and exact medication CNS effects; no protective spacing interval or exact combination risk rate.
- Exact scope
- Oral Piper methysticum products; exact extract, dose and co-ingredients matter. with Exact oral primidone; parent and metabolites distinguished; no other drug/route assumed equivalent.
- Medication form and route
- oral supplement unless pregnancy section explicitly distinguishes neonatal injection
- Timing or duration
- Preparation, dose and duration determine applicability; chronic nutrition evidence is not a single-dose interaction.
What remains uncertain
- No controlled routine co-use safety trial. Withdrawal-treatment reports are a distinct clinical setting and do not establish supplement co-use safety.
Factors that may matter: exact supplement identity; dose; other medicines; clinical indication; baseline nutrition; pregnancy where relevant.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral primidone for epilepsy.
Primidone itself and its phenobarbital and PEMA metabolites have anticonvulsant activity. Drowsiness, ataxia and vertigo can occur. Rare megaloblastic anemia may respond to folic acid without stopping therapy. Label advises maternal vitamin K1 around delivery. Abrupt withdrawal can provoke status epilepticus.
How this applies: Exact RxCUI 8691 IN primidone, UNII 13AFD7670Q, oral tablets.
Parent and metabolites are distinct active exposures. Pregnancy label advice is not proof of benefit for routine prenatal vitamin K or a general adult supplement requirement.
Source 2: current product label
medicines.org.uk · Source check Sep 10, 2026
Population: Patients receiving oral primidone for epilepsy or essential tremor.
Potent CNS depressant; long-term vitamin D supplementation may be needed. Lists folates among co-treatments requiring attention; megaloblastic anemia can respond to folic acid/B12. St John’s wort is listed under contraindicated co-use because primidone concentrations and effectiveness may decrease. Maternal vitamin K1 is advised near delivery.
How this applies: Exact primidone label supports ingredient-specific boundaries rather than inference solely from phenobarbital metabolism.
Does not quantify botanical interactions or make parent and metabolite concentrations equivalent. Maternal vitamin K guidance differs from evidence reviews. No universal supplement spacing.
Source 3: official guidance
nccih.nih.gov · Source check Sep 10, 2026
Population: People considering the specified supplement.
Advises against use with sedative substances. Kava may cause dizziness and has been linked to rare severe liver injury, including with different extraction methods.
How this applies: Preparation-specific context; not a directly measured either requested antiseizure drug interaction.
Not a either requested antiseizure drug study. Intrinsic liver risk does not establish added either requested antiseizure drug hepatotoxicity; preparation and co-exposure vary.
Source 4: randomized placebo-controlled trial
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 391 adults randomized to three groups in an internet-based trial.
Neither active intervention improved its primary anxiety or insomnia outcome more than placebo.
How this applies: Preparation-specific context; not a directly measured either requested antiseizure drug interaction.
Not both active botanicals together, not either requested antiseizure drug co-use. Accessible abstract does not fully characterize dose and preparation; efficacy result is not proof of combination safety.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Exact current available claims reviewed against captured originals; no clinical review asserted. | |
| Research summary published |
Article revision: 24e0d9effbdc564a
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.